<- Go Home
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Market Cap
$14.0B
Volume
816.0K
Cash and Equivalents
$306.9M
EBITDA
-$116.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$387.8M
Profit Margin
56.95%
52 Week High
$131.98
52 Week Low
$64.09
Dividend
N/A
Price / Book Value
12.20
Price / Earnings
-182.12
Price / Tangible Book Value
12.20
Enterprise Value
$13.0B
Enterprise Value / EBITDA
-120.75
Operating Income
-$116.7M
Return on Equity
8.58%
Return on Assets
-6.96
Cash and Short Term Investments
$1.0B
Debt
$17.0M
Equity
$1.1B
Revenue
$680.9M
Unlevered FCF
-$63.5M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium